ジャーナル: iScience / 年: 2022 タイトル: Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways. 著者: Fangzhu Zhao / Celina Keating / Gabriel Ozorowski / Namir Shaabani / Irene M Francino-Urdaniz / Shawn Barman / Oliver Limbo / Alison Burns / Panpan Zhou / Michael J Ricciardi / Jordan Woehl / ...著者: Fangzhu Zhao / Celina Keating / Gabriel Ozorowski / Namir Shaabani / Irene M Francino-Urdaniz / Shawn Barman / Oliver Limbo / Alison Burns / Panpan Zhou / Michael J Ricciardi / Jordan Woehl / Quoc Tran / Hannah L Turner / Linghang Peng / Deli Huang / David Nemazee / Raiees Andrabi / Devin Sok / John R Teijaro / Timothy A Whitehead / Andrew B Ward / Dennis R Burton / Joseph G Jardine / 要旨: The rapid spread of SARS-CoV-2 variants poses a constant threat of escape from monoclonal antibody and vaccine countermeasures. Mutations in the ACE2 receptor binding site on the surface S protein ...The rapid spread of SARS-CoV-2 variants poses a constant threat of escape from monoclonal antibody and vaccine countermeasures. Mutations in the ACE2 receptor binding site on the surface S protein have been shown to disrupt antibody binding and prevent viral neutralization. Here, we used a directed evolution-based approach to engineer three neutralizing antibodies for enhanced binding to S protein. The engineered antibodies showed increased functional activity in terms of neutralization potency and/or breadth of neutralization against viral variants. Deep mutational scanning revealed that higher binding affinity reduces the total number of viral escape mutations. Studies in the Syrian hamster model showed two examples where the affinity-matured antibody provided superior protection compared to the parental antibody. These data suggest that monoclonal antibodies for antiviral indications would benefit from affinity maturation to reduce viral escape pathways and appropriate affinity maturation in vaccine immunization could help resist viral variation.
全体 : CC6.30 Fab in complex with SARS-CoV-2-6P-Mut7 S protein
全体
名称: CC6.30 Fab in complex with SARS-CoV-2-6P-Mut7 S protein
要素
複合体: CC6.30 Fab in complex with SARS-CoV-2-6P-Mut7 S protein
複合体: Spike glycoprotein
タンパク質・ペプチド: Spike glycoprotein
複合体: CC6.30 Fab
タンパク質・ペプチド: CC6.30 Fab heavy chain Fv
タンパク質・ペプチド: CC6.30 Fab kappa chain Fv
リガンド: 2-acetamido-2-deoxy-beta-D-glucopyranose
-
超分子 #1: CC6.30 Fab in complex with SARS-CoV-2-6P-Mut7 S protein
超分子
名称: CC6.30 Fab in complex with SARS-CoV-2-6P-Mut7 S protein タイプ: complex / ID: 1 / 親要素: 0 / 含まれる分子: #1-#3 詳細: Incubated Fab at 9:2 ratio with Spike trimer for about 15 minutes at room temperature